CoChat

A Statin in the Treatment of Heart Failure? Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA): Study Design and Baseline Characteristics

Kjekshus, John, Dunselman, Peter, Blideskog, Malin, Eskilson, Christina, Hjalmarson, Åke, McMurray, John V., Waagstein, Finn, Wedel, Hans, Wessman, Peter, Wikstrand, John · 2005 · European Journal of Heart Failure
Cited by 153

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background: Previous prospective outcome studies of statins have not provided any guidance on benefit-risk in patients with heart failure. Aim: The primary objective is to determine whether rosuvastatin (10 mg) reduces the combined endpoint of cardiovascular mortality, non-fatal myocardial infarction or non-fatal stroke (time to first event). The first secondary endpoint is all-cause mortality. Methods: CORONA is a randomized, double-blind, placebo-controlled trial. Briefly, men and women, aged ≥60 years with chronic symptomatic systolic heart failure of ischemic aetiology and ejection fraction ≤0.40 (NYHA class III and IV) or ≤0.35 (NYHA class II) were eligible if they were not using or in need of cholesterol lowering drugs. Results: Mean age was 73 years (n=5016; 24% women), with 37% in NYHA II and 62% in NYHA III, ejection fraction 0.31, total cholesterol 5.2 mmol/L. Sixty percent have a history of myocardial infarction, 63% hypertension, and 30% diabetes. Patients are well treated for heart failure with 90% on loop or thiazide diuretics, 42% aldosterone antagonists, 91% ACE inhibitor or AT-I blocker, 75% beta-blockers, and 32% digitalis. Conclusion: CORONA is important for three main reasons: (1) A positive result is very important because of the high risk of the population studied, the increasing prevalence of elderly patients with chronic symptomatic systolic heart failure in our society, and the health economic issues involved. (2) If negative, new mechanistic questions about heart failure have to be raised. (3) If neutral we can avoid unnecessary polypharmacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejheart.2005.09.005

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Kjekshus, J., Dunselman, P., Blideskog, M., Eskilson, C., Hjalmarson, Å., McMurray, J. V., Waagstein, F., Wedel, H., Wessman, P., & Wikstrand, J.
Venue
European Journal of Heart Failure
Published
2005-10-01
Volume
7
Issue
6
Pages
1059-1069
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W1995956780
Cited by
153
References
12
FWCI
23.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.